Sotera Health Company (NASDAQ:SHC - Get Free Report) Director Gtcr Investment Xi Llc sold 8,000,000 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $15.11, for a total transaction of $120,880,000.00. Following the sale, the director directly owned 41,215,301 shares in the company, valued at $622,763,198.11. The trade was a 16.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Sotera Health Stock Performance
SHC stock traded down $0.07 during midday trading on Friday, reaching $16.05. 2,486,837 shares of the company's stock traded hands, compared to its average volume of 2,383,320. The company has a 50-day moving average price of $13.78 and a two-hundred day moving average price of $12.42. The company has a debt-to-equity ratio of 4.49, a quick ratio of 2.23 and a current ratio of 2.47. Sotera Health Company has a 52 week low of $9.53 and a 52 week high of $16.99. The firm has a market capitalization of $4.56 billion, a PE ratio of 200.65 and a beta of 1.84.
Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.03. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The business had revenue of $294.34 million for the quarter, compared to analysts' expectations of $275.81 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The business's revenue for the quarter was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, equities analysts anticipate that Sotera Health Company will post 0.61 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on SHC. Barclays reaffirmed an "overweight" rating on shares of Sotera Health in a report on Friday, August 8th. Wall Street Zen raised shares of Sotera Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.00.
Get Our Latest Stock Report on Sotera Health
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its stake in Sotera Health by 33.1% in the second quarter. Caitong International Asset Management Co. Ltd now owns 3,583 shares of the company's stock valued at $40,000 after acquiring an additional 892 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Sotera Health by 4.1% in the second quarter. Teacher Retirement System of Texas now owns 23,707 shares of the company's stock valued at $264,000 after acquiring an additional 933 shares during the last quarter. Principal Financial Group Inc. increased its stake in Sotera Health by 0.3% in the first quarter. Principal Financial Group Inc. now owns 352,388 shares of the company's stock valued at $4,109,000 after acquiring an additional 1,037 shares during the last quarter. Optimize Financial Inc increased its stake in Sotera Health by 7.7% in the first quarter. Optimize Financial Inc now owns 14,545 shares of the company's stock valued at $170,000 after acquiring an additional 1,041 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in Sotera Health by 1.9% in the first quarter. New York State Teachers Retirement System now owns 59,273 shares of the company's stock valued at $691,000 after acquiring an additional 1,100 shares during the last quarter. Institutional investors own 91.03% of the company's stock.
Sotera Health Company Profile
(
Get Free Report)
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
See Also
Before you consider Sotera Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sotera Health wasn't on the list.
While Sotera Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.